1. REVASCULARIZATION TRENDS IN PATIENTS WITH DIABETES MELLITUS AND MULTIVESSEL CORONARY ARTERY DISEASE PRESENTING WITH NON-ST ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE NCDR®

    Journal of the American College of Cardiology 65(10):A22 (2015)

  2. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

    JAMA 312(21):2223 (2014) PMID 25402495

    Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. To evaluate the efficacy and safety of zirconium cyclosil...
  3. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

    JAMA 312(21):2223 (2014) PMID 25402495

    Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. To evaluate the efficacy and safety of zirconium cyclosil...
  4. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

    JAMA 312(21):2223 (2014) PMID 25402495

    Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. To evaluate the efficacy and safety of zirconium cyclosil...
  5. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry.

    Journal of the American Heart Association Cardi... 3(6):e001380 (2014) PMID 25516439

    We developed risk models for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI‐D) after percutaneous coronary intervention (PCI) to support quality assessment and the use of preventative strategies. AKI was defined as an absolute increase of ≥0.3 mg/dL or a relative increase o...
  6. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry.

    Journal of the American Heart Association Cardi... 3(6):e001380 (2014) PMID 25516439 PMCID PMC4338731

    We developed risk models for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI‐D) after percutaneous coronary intervention (PCI) to support quality assessment and the use of preventative strategies. AKI was defined as an absolute increase of ≥0.3 mg/dL or a relative increase o...
  7. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry.

    Journal of the American Heart Association Cardi... 3(6):e001380 (2014) PMID 25516439 PMCID PMC4338731

    We developed risk models for predicting acute kidney injury (AKI) and AKI requiring dialysis (AKI‐D) after percutaneous coronary intervention (PCI) to support quality assessment and the use of preventative strategies. AKI was defined as an absolute increase of ≥0.3 mg/dL or a relative increase o...
  8. Glycemic control and excess mortality in type 1 diabetes.

    New England Journal of Medicine 371(21):1972 (2014) PMID 25409370

    The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic contro...
  9. Glycemic control and excess mortality in type 1 diabetes.

    New England Journal of Medicine 371(21):1972 (2014) PMID 25409370

    The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic contro...
  10. Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.

    Circulation: Cardiovascular Quality and Outcomes 7(6):844 (2014) PMID 25249560

    As new techniques emerge to quantify patients' health status, new opportunities are created to validate patient-reported outcome questionnaires. The Seattle Angina Questionnaire (SAQ), a widely used coronary artery disease-specific health status tool, has not been validated against daily records...
  11. Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.

    Circulation: Cardiovascular Quality and Outcomes 7(6):844 (2014) PMID 25249560

    As new techniques emerge to quantify patients' health status, new opportunities are created to validate patient-reported outcome questionnaires. The Seattle Angina Questionnaire (SAQ), a widely used coronary artery disease-specific health status tool, has not been validated against daily records...
  12. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction.

    American Heart Journal 168(4):466 (2014) PMID 25262255 PMCID PMC4180044

    Patients with an acute myocardial infarction (AMI) who have glucose abnormalities are at increased risk for death and adverse ischemic outcomes. The contemporary prevalence of glucose abnormalities among AMI patients in the United States, as determined by hemoglobin A1c (HbA1c), is unknown. Pati...
  13. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction.

    American Heart Journal 168(4):466 (2014) PMID 25262255 PMCID PMC4180044

    Patients with an acute myocardial infarction (AMI) who have glucose abnormalities are at increased risk for death and adverse ischemic outcomes. The contemporary prevalence of glucose abnormalities among AMI patients in the United States, as determined by hemoglobin A1c (HbA1c), is unknown. Pati...
  14. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.

    American Heart Journal 168(4):457 (2014) PMID 25262254

    Ranolazine reduces the frequency of angina and use of sublingual nitroglycerin (SL NTG) in stable angina patients with type 2 diabetes (T2DM). Because pre-clinical data suggest that myocardial late sodium current (INaL), the target of ranolazine, is increased by hyperglycemia, we investigated wh...
  15. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.

    American Heart Journal 168(4):457 (2014) PMID 25262254

    Ranolazine reduces the frequency of angina and use of sublingual nitroglycerin (SL NTG) in stable angina patients with type 2 diabetes (T2DM). Because pre-clinical data suggest that myocardial late sodium current (INaL), the target of ranolazine, is increased by hyperglycemia, we investigated wh...
  16. Type of β-blocker use among patients with versus without diabetes after myocardial infarction.

    American Heart Journal 168(3):273 (2014) PMID 25173537 PMCID PMC4151261

    Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. Numerous β-blocker choices are presently available with variable glycometabolic effects, which could be an important consideration in patients with diabetes mellitus (DM). Whether patients...
  17. Type of β-blocker use among patients with versus without diabetes after myocardial infarction

    American Heart Journal 168(3):273 (2014)

    Background Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. Numerous β-blocker choices are presently available with variable glycometabolic effects, which could be an important consideration in patients with diabetes ...
  18. Blood Transfusion During Acute Myocardial Infarction: Association With Mortality and Variability Across Hospitals

    Journal of the American College of Cardiology 64(8):811 (2014)

    Background Blood transfusion is controversial for anemic patients with acute myocardial infarction (AMI), with some previous studies reporting increased risk of transfusion-associated mortality.
  19. Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals.

    Journal of the American College of Cardiology 64(8):811 (2014) PMID 25145526

    Blood transfusion is controversial for anemic patients with acute myocardial infarction (AMI), with some previous studies reporting increased risk of transfusion-associated mortality. The goal of this study was to examine variability in blood transfusions across hospitals and the relationship be...
  20. Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina.

    JAMA Internal Medicine 174(8):1403 (2014) PMID 24887304